» Articles » PMID: 27799249

Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2016 Nov 2
PMID 27799249
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC) or the factors that draw MDSC into tumor parenchyma. We analyzed polymorphonuclear MDSC (PMN-MDSC), monocytic MDSC (M-MDSC), and immature MDSC (I-MDSC) from the parenchyma and peripheral blood of 48 patients with RCC, isolated at nephrectomy. We analyzed levels of IL1β, IL8, CXCL5, Mip-1α, MCP-1, and Rantes. Furthermore, we performed experiments in a Renca murine model to assess therapeutic synergy between CXCR2 and anti-PD1 and to elucidate the impact of IL1β blockade on MDSC. Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, and I-MDSC correlate with IL8 and CXCL5. Furthermore, peripheral PMN-MDSC correlate with tumor grade. Given that PMN-MDSC express CXCR2 and parenchymal PMN-MDSC correlated with IL8 and CXCL5, we assessed the response of CXCR2 blockade with or without anti-PD1. Combination therapy reduced tumor weight and enhanced CD4 and CD8 T-cell infiltration. In addition, anti-IL1β decreased PMN-MDSC and M-MDSC in the periphery, PMN-MDSC in the tumor, and peripheral CXCL5 and KC. Anti-IL1β also delayed tumor growth. Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, suggesting they may attract PMN-MDSC into the tumor. Peripheral PMN-MDSC correlate with tumor grade, suggesting prognostic significance. Anti-CXCR2 and anti-PD1 synergized to reduce tumor weight and enhanced CD4 and CD8 T-cell infiltration in a Renca murine model, suggesting that CXCR2 PMN-MDSC are important in reducing activity of anti-PD1 antibody. Finally, anti-IL1β decreases MDSC and delayed tumor growth, suggesting a potential target for MDSC inhibition. .

Citing Articles

Multi-omics association study integrating GWAS and pQTL data revealed MIP-1α as a potential drug target for erectile dysfunction.

Liu J, Pan R Front Pharmacol. 2024; 15:1495970.

PMID: 39555095 PMC: 11565697. DOI: 10.3389/fphar.2024.1495970.


Toward a CRISPR-based mouse model of -deficient clear cell kidney cancer: Initial experience and lessons learned.

Stransky L, Gao W, Schmidt L, Bi K, Ricketts C, Ramesh V Proc Natl Acad Sci U S A. 2024; 121(41):e2408549121.

PMID: 39365820 PMC: 11474080. DOI: 10.1073/pnas.2408549121.


Evaluation of the clinical significance of lymphocyte subsets and myeloid suppressor cells in patients with renal carcinoma.

Li Y, Wu Z, Ni C, Li Y, Wang P Discov Oncol. 2024; 15(1):512.

PMID: 39347882 PMC: 11442913. DOI: 10.1007/s12672-024-01405-2.


Pre-metastatic niche: formation, characteristics and therapeutic implication.

Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q Signal Transduct Target Ther. 2024; 9(1):236.

PMID: 39317708 PMC: 11422510. DOI: 10.1038/s41392-024-01937-7.


Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.

Wang Z, Zhou L, Wu X Oncol Res. 2024; 32(9):1479-1516.

PMID: 39220130 PMC: 11361912. DOI: 10.32604/or.2024.048564.


References
1.
Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

2.
Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

3.
Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H . Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008; 118(10):3367-77. PMC: 2528912. DOI: 10.1172/JCI35213. View

4.
Kowalczuk O, Burzykowski T, Niklinska W, Kozlowski M, Chyczewski L, Niklinski J . CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour Biol. 2014; 35(5):4619-28. PMC: 4009141. DOI: 10.1007/s13277-014-1605-x. View

5.
Obermajer N, Muthuswamy R, Odunsi K, Edwards R, Kalinski P . PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011; 71(24):7463-70. PMC: 4993027. DOI: 10.1158/0008-5472.CAN-11-2449. View